Compare CSTM & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTM | ARQT |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | France | United States |
| Employees | 12000 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.3B |
| IPO Year | 2012 | 2020 |
| Metric | CSTM | ARQT |
|---|---|---|
| Price | $25.34 | $25.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $29.00 | $25.00 |
| AVG Volume (30 Days) | ★ 1.9M | 1.1M |
| Earning Date | 05-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.31 |
| EPS | ★ 1.13 | N/A |
| Revenue | ★ $7,335,000,000.00 | $196,542,000.00 |
| Revenue This Year | N/A | $86.38 |
| Revenue Next Year | $3.46 | $30.29 |
| P/E Ratio | $22.85 | ★ N/A |
| Revenue Growth | N/A | ★ 229.74 |
| 52 Week Low | $7.33 | $11.86 |
| 52 Week High | $27.25 | $31.77 |
| Indicator | CSTM | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 64.25 | 54.73 |
| Support Level | $22.32 | $26.28 |
| Resistance Level | $27.25 | $26.97 |
| Average True Range (ATR) | 1.23 | 1.07 |
| MACD | -0.01 | 0.21 |
| Stochastic Oscillator | 63.79 | 82.52 |
Constellium SE is engaged in the design and manufacture of rolled and extruded aluminium products, serving the packaging, aerospace, automotive, defence and other transportation and industry end-markets. The business is organized into three operating segments: the Packaging and Automotive Rolled Products segment which includes the production of rolled aluminium sheet products in European and North American facilities; the Aerospace and Transportation segment includes the production of rolled aluminium products and very limited volumes of extruded products in European and North American facilities; the Automotive Structures and Industry segment includes the production of extruded aluminium products and aluminium structural components.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.